denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Biological therapies, Fundamental Science, Clinical Practice (Health Services and Quality), Diseases, Gene Therapy, Therapies, Biological Processes, Technology and Procedures, gene editing, Transfusion
Description:
Emerging technologies are rapidly changing the landscape of diagnosis and therapies in genetic and acquired bleeding disorders. This session will focus on technologies that align with the ASH Research Agenda (including gene editing, vascular biology, and computational analysis in hematology) and features a group of researchers who are at the forefront of developing and/or using these technologies for blood research. Their talks will focus on addressing gene editing of platelets, advanced biomaterials to promote hemostasis in traumatic bleeding, and fluid flow-based diagnostics of von Willebrand factor (VWF) function.
Dr. Christian Kastrup will discuss how platelets fulfill specialized roles in coagulation and hemostasis, their integral role in hemorrhage management, and their potential for diverse applications as cell therapies in the future. Since methods to genetically modify platelets do not currently exist, Dr. Kastrup will expand on the work done in his lab and how him and his team have created an mRNA-based technology to produce exogenous proteins in transfusable platelets, by optimizing lipid nanoparticles, nucleotide modifications, and various RNA elements to promote transfection and translation within donor platelets.
Dr. Ashley Brown will discuss novel engineered biomaterials for promoting hemostasis. She will describe the development and characterization of platelet-like-particles that target fibrin to stop bleeding and promote healing. Dr. Brown will discuss the efficacy, safety, and clearance of these particles in treating bleeding following intravenous injection in small and large animal models of trauma. Lastly, Dr. Brown will also discuss their influence on healing outcomes.
Dr. David Bark will review VWF degradation and the flow mechanisms that drive it. He will discuss microfluidic device designs that can test VWF function in a laboratory environment and how function relates to structure. Lastly, Dr. Bark will examine flow-based point-of-care VWF assessment approaches.
Dr. Christian Kastrup will discuss how platelets fulfill specialized roles in coagulation and hemostasis, their integral role in hemorrhage management, and their potential for diverse applications as cell therapies in the future. Since methods to genetically modify platelets do not currently exist, Dr. Kastrup will expand on the work done in his lab and how him and his team have created an mRNA-based technology to produce exogenous proteins in transfusable platelets, by optimizing lipid nanoparticles, nucleotide modifications, and various RNA elements to promote transfection and translation within donor platelets.
Dr. Ashley Brown will discuss novel engineered biomaterials for promoting hemostasis. She will describe the development and characterization of platelet-like-particles that target fibrin to stop bleeding and promote healing. Dr. Brown will discuss the efficacy, safety, and clearance of these particles in treating bleeding following intravenous injection in small and large animal models of trauma. Lastly, Dr. Brown will also discuss their influence on healing outcomes.
Dr. David Bark will review VWF degradation and the flow mechanisms that drive it. He will discuss microfluidic device designs that can test VWF function in a laboratory environment and how function relates to structure. Lastly, Dr. Bark will examine flow-based point-of-care VWF assessment approaches.